Leerink Swann Starts ProQR Therapeutics N.V. (PRQR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Deutsche Bank Starts ProQR Therapeutics N.V. (PRQR) at Buy
October 15, 2014 7:10 AM EDTDeutsche Bank initiates coverage on ProQR Therapeutics N.V. (NASDAQ: PRQR) with a Buy rating and a price target of $32.00.
Analyst Alethia Young said, "Cystic fibrosis (CF) drug development is in a renaissance era with rapid progress in the past few years led... More
JMP Securities Starts ProQR Therapeutics N.V. (PRQR) at Market Outperform
October 14, 2014 7:30 AM EDTJMP Securities initiated coverage on ProQR Therapeutics N.V. (NASDAQ: PRQR) with a Market Outperform rating and a price target of $36.00.
For an analyst ratings summary and ratings history on ProQR Therapeutics N.V.... More
H.C. Wainwright Starts ProQR Therapeutics N.V. (PRQR) at Buy
October 13, 2014 9:38 AM EDTH.C. Wainwright initiated coverage on ProQR Therapeutics N.V. (NASDAQ: PRQR) with a Buy rating and a price target of $40.00. Analyst Andrew S. Fein noted a strong preclinical debut at NACFC 2014 last week.
"Distancing itself from the growing pack of companies with CFTR potentiators and correctors, ProQR employs antisense technology to correct the F508 CFTR mutation at the mRNA level.... More
